Advertisement

CollPlant Biotechnologies Ltd. CLGN

Set alert

Price alert · CLGN

All alert types
4.14 USD -0.27 -6.02%

At close · Oct 30

4.10 -0.04 -0.85%

After hours · Oct 30, 4:00 PM ET

Bid
4.10 × 1
Ask
4.20 × 1
4.10 Day range 4.60
2.73 52-week range 22.80
YTD
-70.46%
1 year
-81.12%
Open
4.20
Prev close
4.40
Mkt cap
11.91M
Vol
44.25K
Avg vol
365.75K
EPS
-9.33
P/E
0.00
Div yield
0.00%
More statistics
Low
4.10
High
4.60
Forward P/E
-8.82
Beta
0.48
Short ratio
0.70
Inst. own
12.23%
Dividend
0.00
Ex-div date
Earnings
Aug 20, 2024
50-d avg
4.04
200-d avg
4.90
1y target
12.50

2Y chart

Chart tools
Interval

Events in this range
  • Nov 27, 2024Rating: D. Boral Capital · Buy → Buy
  • Nov 27, 2024Earnings: -0.38; estimate -0.37; surprise -2.7%
  • Nov 29, 2024Rating: HC Wainwright & Co. · Buy → Buy
  • Sep 4, 2026Split: 1 for 10
Signals (73)
NameDateAgo
MACD: Buy SignalOct 28, 20264 days ago
MACD: Sell SignalOct 16, 20262 weeks ago
MACD: Buy SignalOct 14, 20262 weeks ago
SMA: BullishOct 7, 20263 weeks ago
SMA: BearishOct 5, 20263 weeks ago
MACD: Sell SignalSep 29, 20261 month ago
RSI: OverboughtSep 18, 20261 month ago
SMA: BullishAug 28, 20262 months ago
MACD: Buy SignalAug 28, 20262 months ago
MACD: Sell SignalAug 25, 20262 months ago
MACD: Buy SignalAug 6, 20262 months ago
MACD: Sell SignalJul 17, 20263 months ago
SMA: BearishJul 7, 20263 months ago
SMA: BullishJul 6, 20263 months ago
MACD: Buy SignalJun 25, 20264 months ago
RSI: OversoldJun 11, 20264 months ago
MACD: Sell SignalJun 4, 20265 months ago
MACD: Buy SignalApr 20, 20266 months ago
RSI: OversoldApr 13, 20266 months ago
MACD: Sell SignalApr 7, 20266 months ago
RSI: OversoldApr 6, 20266 months ago
MACD: Buy SignalMar 2, 20268 months ago
MACD: Sell SignalFeb 5, 20268 months ago
RSI: OversoldFeb 5, 20268 months ago
SMA: BearishFeb 3, 20269 months ago
SMA: BullishJan 23, 20269 months ago
MACD: Buy SignalJan 2, 202610 months ago
RSI: OversoldDec 16, 202510 months ago
MACD: Sell SignalDec 8, 202510 months ago
MACD: Buy SignalNov 18, 202511 months ago
MACD: Sell SignalOct 29, 20251 year ago
MACD: Buy SignalOct 27, 20251 year ago
MACD: Sell SignalOct 22, 20251 year ago
MACD: Buy SignalOct 21, 20251 year ago
SMA: BearishOct 1, 20251 year ago
MACD: Sell SignalOct 1, 20251 year ago
SMA: BearishSep 30, 20251 year ago
MACD: Buy SignalSep 26, 20251 year ago
SMA: BullishSep 25, 20251 year ago
SMA: BearishAug 28, 20251 year ago
SMA: BullishAug 27, 20251 year ago
SMA: BullishAug 21, 20251 year ago
SMA: BearishAug 20, 20251 year ago
MACD: Sell SignalAug 15, 20251 year ago
RSI: OverboughtAug 6, 20251 year ago
RSI: OverboughtJul 23, 20251 year ago
SMA: BullishJul 16, 20251 year ago
MACD: Buy SignalJul 7, 20251 year ago
MACD: Sell SignalJun 6, 20251 year ago
SMA: BearishJun 4, 20251 year ago
SMA: BullishJun 3, 20251 year ago
SMA: BearishJun 2, 20251 year ago
SMA: BullishMay 28, 20251 year ago
RSI: OverboughtMay 28, 20251 year ago
MACD: Buy SignalMay 19, 20251 year ago
MACD: Sell SignalMay 7, 20251 year ago
RSI: OversoldMay 6, 20251 year ago
RSI: OversoldApr 30, 20251 year ago
MACD: Buy SignalApr 25, 20251 year ago
MACD: Sell SignalApr 23, 20251 year ago
RSI: OversoldApr 16, 20251 year ago
MACD: Buy SignalApr 11, 20251 year ago
RSI: OversoldApr 10, 20251 year ago
RSI: OversoldMar 26, 20251 year ago
MACD: Sell SignalMar 25, 20251 year ago
MACD: Buy SignalMar 14, 20251 year ago
RSI: OversoldMar 5, 20251 year ago
SMA: BearishJan 23, 20251 year ago
MACD: Sell SignalJan 23, 20251 year ago
SMA: BullishJan 15, 20251 year ago
RSI: OverboughtJan 7, 20251 year ago
MACD: Buy SignalJan 2, 20251 year ago
RSI: OverboughtNov 29, 20241 year ago

Key statistics

Market cap
39.40M
Enterprise value
33.32M
Trailing P/E
0.00
Forward P/E
-8.82
PEG ratio
0.00
Price / sales
57.19
Price / book
1.39
EPS (TTM)
-1.53
Beta
0.48
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
689.00K
Revenue growth
-97.60%
Free cash flow
2.13M
Total cash
18.92M
Total debt
3.38M
Return on equity
-61.55%
Shares outstanding
11.45M
Short % of float
0.15%
50-day average
4.04
200-day average
4.90

Analyst view

Consensus: none

Price target (mean) 12.50 +202.3% upside
Target (low)
11.00
Target (mean)
12.50
Target (high)
14.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
  • Strong buy1
  • Buy1
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Aug 20, 2024

Expected Aug 20, 2024. Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
CLGN Revenue — quarterly 108.00K
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
CLGN Net income — quarterly -2.73M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
CLGN EPS — quarterly -1.89
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

CLGN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 27, 2024Sep 1, 2024-0.37-0.38-0.01-2.70%
Aug 20, 2024Jun 1, 2024-0.35-0.37-0.02-5.71%
Aug 20, 2024Jun 1, 2024-0.35———
May 29, 2024Mar 1, 2024-0.35-0.37-0.02-5.71%
May 29, 2024Mar 1, 2024-0.35———
Apr 4, 2024Dec 1, 20230.00-0.42——

Upgrades / downgrades

CLGN analyst upgrades and downgrades
DateFirmActionFromTo
Nov 29, 2024HC Wainwright & Co.reitBuyBuy
Nov 27, 2024D. Boral CapitalmainBuyBuy
Aug 21, 2024HC Wainwright & Co.reitBuyBuy
Aug 20, 2024EF HuttonmainBuyBuy
Aug 5, 2024EF Huttoninit—Buy
May 30, 2024HC Wainwright & Co.reitBuyBuy

About CollPlant Biotechnologies Ltd.

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.

Sector
Healthcare
Industry
Biotechnology
Country
Israel

News

Your note

Sign in to keep a note on CLGN — it syncs with the Stock Master app.

Institution ownership

CLGN institution ownership
Holder% heldSharesValueReported
Villere St. Denis J. & Co. LLC4.33%484,8671.67MSep 29, 2024
Pinnacle Associates, Ltd.4.18%468,1091.61MSep 29, 2024
Brown Advisory Inc.1.07%119,465410.96KSep 29, 2024
AMH Equity Ltd.0.89%99,205341.26KSep 29, 2024
Benjamin Edwards, Inc.0.21%23,81081.91KSep 29, 2024
Pathstone Holdings, LLC0.15%17,00058.48KSep 29, 2024

Fund ownership

CLGN fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.05%5,92520.38KOct 30, 2024
Advertisement